Saltar al contenido
Merck

Fixed-dose combination of phentermine-topiramate for the treatment of obesity.

Expert review of clinical pharmacology (2013-05-10)
Bruno Halpern, André M Faria, Alfredo Halpern
RESUMEN

The aim of this article is to focus on the fixed-dose combination of phentermine and topiramate, a new antiobesity drug recently approved by the US FDA. The mechanisms of weight loss for each drug in monotherapy is described, followed by the rationale for its use as a combination therapy and a comprehensive review of recently published clinical trials that assessed its efficacy  and safety.

MATERIALES
Referencia del producto
Marca
Descripción del producto

USP
Topiramate, United States Pharmacopeia (USP) Reference Standard
Supelco
Topiramate solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®
Sigma-Aldrich
Topiramate, ≥98% (HPLC), solid